Neurocrine Biosciences, Inc. (BVMF:N1BI34)
Brazil
· Delayed Price · Currency is BRL 33.57
-1.20 (-3.45%)
At close: Mar 6, 2026
Neurocrine Biosciences Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 713 | 233 | 251.1 | 262.9 | 340.8 | Upgrade
|
| Short-Term Investments | 767.4 | 843.1 | 780.5 | 726.4 | 370.5 | Upgrade
|
| Cash & Short-Term Investments | 1,480 | 1,076 | 1,032 | 989.3 | 711.3 | Upgrade
|
| Cash Growth | 37.57% | 4.31% | 4.28% | 39.08% | -11.20% | Upgrade
|
| Receivables | 686.8 | 479.1 | 439.3 | 350 | 185.5 | Upgrade
|
| Inventory | 69 | 57.4 | 38.3 | 35.1 | 30.5 | Upgrade
|
| Prepaid Expenses | 170.7 | 48.5 | - | - | - | Upgrade
|
| Other Current Assets | 115.8 | 63.6 | 97.8 | 79.1 | 45.5 | Upgrade
|
| Total Current Assets | 2,523 | 1,725 | 1,607 | 1,454 | 972.8 | Upgrade
|
| Property, Plant & Equipment | 545.2 | 592 | 347.3 | 145.6 | 155.8 | Upgrade
|
| Long-Term Investments | 1,184 | 864.3 | 849.4 | 401.5 | 624.4 | Upgrade
|
| Goodwill | - | - | 5.8 | 5.4 | - | Upgrade
|
| Other Intangible Assets | - | - | 35.5 | 37.2 | - | Upgrade
|
| Long-Term Deferred Tax Assets | 320.3 | 485.7 | 362.6 | 305.9 | 315.1 | Upgrade
|
| Other Long-Term Assets | 59.5 | 52 | 43.8 | 19.6 | 4.4 | Upgrade
|
| Total Assets | 4,632 | 3,719 | 3,251 | 2,369 | 2,073 | Upgrade
|
| Accounts Payable | 104.9 | 99.9 | 133.3 | 67.3 | 51.5 | Upgrade
|
| Accrued Expenses | 501.4 | 351.7 | 315.5 | 271.3 | 111.6 | Upgrade
|
| Current Portion of Long-Term Debt | - | - | 170.1 | 169.4 | - | Upgrade
|
| Current Portion of Leases | 56 | - | - | - | - | Upgrade
|
| Current Income Taxes Payable | 68 | 10 | - | 9 | - | Upgrade
|
| Current Unearned Revenue | - | - | - | - | 62.7 | Upgrade
|
| Other Current Liabilities | 13.1 | 46.1 | 35.9 | 20.7 | 20 | Upgrade
|
| Total Current Liabilities | 743.4 | 507.7 | 654.8 | 537.7 | 245.8 | Upgrade
|
| Long-Term Debt | - | - | - | - | 335.1 | Upgrade
|
| Long-Term Leases | 415.3 | 455.1 | 258.3 | 93.5 | 105.3 | Upgrade
|
| Other Long-Term Liabilities | 219.7 | 166.2 | 106.3 | 29.7 | 12.3 | Upgrade
|
| Total Liabilities | 1,378 | 1,129 | 1,019 | 660.9 | 698.5 | Upgrade
|
| Common Stock | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | Upgrade
|
| Additional Paid-In Capital | 2,792 | 2,555 | 2,382 | 2,122 | 2,011 | Upgrade
|
| Retained Earnings | 447.7 | 29.2 | -157.1 | -406.8 | -635.8 | Upgrade
|
| Comprehensive Income & Other | 13.1 | 5.8 | 7 | -7.9 | -1.7 | Upgrade
|
| Shareholders' Equity | 3,253 | 2,590 | 2,232 | 1,708 | 1,374 | Upgrade
|
| Total Liabilities & Equity | 4,632 | 3,719 | 3,251 | 2,369 | 2,073 | Upgrade
|
| Total Debt | 471.3 | 455.1 | 428.4 | 262.9 | 440.4 | Upgrade
|
| Net Cash (Debt) | 1,009 | 621 | 603.2 | 726.4 | 270.9 | Upgrade
|
| Net Cash Growth | 62.50% | 2.95% | -16.96% | 168.14% | -30.31% | Upgrade
|
| Net Cash Per Share | 9.84 | 5.99 | 5.97 | 7.34 | 2.77 | Upgrade
|
| Filing Date Shares Outstanding | 100.36 | 99.7 | 99.51 | 96.59 | 95.24 | Upgrade
|
| Total Common Shares Outstanding | 100.1 | 99.4 | 98.7 | 96.5 | 94.9 | Upgrade
|
| Working Capital | 1,779 | 1,217 | 952.2 | 915.8 | 727 | Upgrade
|
| Book Value Per Share | 32.50 | 26.05 | 22.61 | 17.70 | 14.48 | Upgrade
|
| Tangible Book Value | 3,253 | 2,590 | 2,191 | 1,665 | 1,374 | Upgrade
|
| Tangible Book Value Per Share | 32.50 | 26.05 | 22.20 | 17.26 | 14.48 | Upgrade
|
| Machinery | 172.5 | 153.2 | 115.7 | 87 | 75.6 | Upgrade
|
| Leasehold Improvements | 35.6 | 35.9 | 38.1 | 37.9 | 34.9 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.